The study found that the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and chemokines were significantly increased in IFNα-treated CHC patients with TD, and these cytokines have immune function-enhancing effects [26]. The gene discussed is IL6; the disease is thanatophoric dysplasia.